These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 22650360

  • 21. Effects of zoledronic acid and geranylgeraniol on the cellular behaviour and gene expression of primary human alveolar osteoblasts.
    Zafar S, Coates DE, Cullinan MP, Drummond BK, Milne T, Seymour GJ.
    Clin Oral Investig; 2016 Nov; 20(8):2023-2035. PubMed ID: 26795621
    [Abstract] [Full Text] [Related]

  • 22. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
    Morgan C, Lewis PD, Jones RM, Bertelli G, Thomas GA, Leonard RC.
    Acta Oncol; 2007 Nov; 46(5):669-77. PubMed ID: 17562444
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
    Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH.
    Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.
    Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC.
    Cancer Res; 2000 Nov 01; 60(21):6001-7. PubMed ID: 11085520
    [Abstract] [Full Text] [Related]

  • 27. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
    Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A.
    Haematologica; 2006 Jul 01; 91(7):968-71. PubMed ID: 16757414
    [Abstract] [Full Text] [Related]

  • 28. Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells.
    Tanaka T, Kawashima H, Ohnishi K, Matsumura K, Yoshimura R, Matsuyama M, Kuratsukuri K, Nakatani T.
    Anticancer Res; 2009 Apr 01; 29(4):1089-94. PubMed ID: 19414350
    [Abstract] [Full Text] [Related]

  • 29. Zoledronic acid inhibits human osteoblast activities.
    Basso FG, Silveira Turrioni AP, Hebling J, de Souza Costa CA.
    Gerontology; 2013 Apr 01; 59(6):534-41. PubMed ID: 23867757
    [Abstract] [Full Text] [Related]

  • 30. Bisphosphonate Modulation of the Gene Expression of Different Markers Involved in Osteoblast Physiology: Possible Implications in Bisphosphonate-Related Osteonecrosis of the Jaw.
    Manzano-Moreno FJ, Ramos-Torrecillas J, Melguizo-Rodríguez L, Illescas-Montes R, Ruiz C, García-Martínez O.
    Int J Med Sci; 2018 Apr 01; 15(4):359-367. PubMed ID: 29511371
    [Abstract] [Full Text] [Related]

  • 31. Response of a co-culture model of epithelial cells and gingival fibroblasts to zoledronic acid.
    Basso FG, Soares DG, Pansani TN, Turrioni AP, Scheffel DL, Hebling J, Costa CA.
    Braz Oral Res; 2016 Nov 28; 30(1):e122. PubMed ID: 27901204
    [Abstract] [Full Text] [Related]

  • 32. Cytoprotective effects of melatonin on zoledronic acid-treated human osteoblasts.
    Camacho-Alonso F, Urrutia-Rodríguez I, Oñate-Cabrerizo D, Oñate-Sánchez RE, Rodríguez-Lozano FJ.
    J Craniomaxillofac Surg; 2017 Aug 28; 45(8):1251-1257. PubMed ID: 28552199
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro.
    Walter C, Pabst A, Ziebart T, Klein M, Al-Nawas B.
    Oral Dis; 2011 Mar 28; 17(2):194-9. PubMed ID: 20796232
    [Abstract] [Full Text] [Related]

  • 35. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
    Estilo CL, Van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, Riedel ER, Carlson DL, Schoder H, Farooki A, Fornier M, Halpern JL, Tunick SJ, Huryn JM.
    Oncologist; 2008 Aug 28; 13(8):911-20. PubMed ID: 18695259
    [Abstract] [Full Text] [Related]

  • 36. The bisphosphonate zoledronic acid regulates key angiogenesis-related genes in primary human gingival fibroblasts.
    Ohlrich EJ, Coates DE, Cullinan MP, Milne TJ, Zafar S, Zhao Y, Duncan WD, Seymour GJ.
    Arch Oral Biol; 2016 Mar 28; 63():7-14. PubMed ID: 26658366
    [Abstract] [Full Text] [Related]

  • 37. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P.
    Clin Ther; 2007 Aug 28; 29(8):1548-58. PubMed ID: 17919538
    [Abstract] [Full Text] [Related]

  • 38. Inhibition of osteoblast function in vitro by aminobisphosphonates.
    Orriss IR, Key ML, Colston KW, Arnett TR.
    J Cell Biochem; 2009 Jan 01; 106(1):109-18. PubMed ID: 19003973
    [Abstract] [Full Text] [Related]

  • 39. Histomorphometric evaluation of the effects of zoledronic acid on mandibular distraction osteogenesis in rabbits.
    Pampu AA, Dolanmaz D, Tüz HH, Avunduk MC, Kişnişci RS.
    J Oral Maxillofac Surg; 2008 May 01; 66(5):905-10. PubMed ID: 18423279
    [Abstract] [Full Text] [Related]

  • 40. Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis.
    Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF.
    Br J Haematol; 2009 Mar 01; 144(5):667-76. PubMed ID: 19036117
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.